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Abstract 22 
Ethnopharmacological relevance: B. boliviensis and B. tola are used in traditional medicine in the 23 
Argentine Puna to treat skin and soft tissue infections and inflammatory processes in humans and 24 
animals.  25 
Aim of the study: To assess the potential of phytotherapeutic preparations of Baccharis species as 26 
antifungal agents against clinically relevant fungi and to determine the chemical composition of 27 
the extracts.  28 
Material and methods: Phytotherapeutic preparations of B. boliviensis and B. tola collected in 29 
Argentine Puna were evaluated as an antifungal agent against clinically relevant fungi (yeast, non-30 
dermatophytes, and dermatophytes) isolated of patients from a local Hospital, and reference 31 
strains, using macrodilution and microdilution assay . The bioactivity was supported by UHPLC-32 
OT-MS metabolome fingerprinting.  33 
Results: The results revealed that the plant preparations were active against most of evaluated 34 
fungal strains; B. boliviensis was more active than B. tola. Dermatophyte fungi strains were the 35 
most sensitive isolates. The phytotherapeutic preparation showed Minimal Inhibitory 36 
Concentration (MIC) values between 25-400 µg GAE/mL and Minimum Fungicidal Concentration 37 
(MFC) values between 50 and 400 µg GAE/mL. Regarding the phytochemical analysis, total 38 
phenolic and total flavonoid contents of hydroalcoholic preparation of B. boliviensis were greater 39 
than those of the B. tola extract. Both Baccharis species showed similar chromatographic patterns, 40 
fifty-two compounds were identified based on UHPLC-OT MS including several terpenoids, 41 
flavonoids and phenolic acids that have been identifi d in this two endemic South American 42 
Baccharis species for the first time. Several identified comp unds present antifungal properties, 43 
the presence of these compounds support the bioactivity of the Baccharis extracts. 44 
Conclusions: In this work the traditional use of both Baccharis species as an antimicrobial against 45 
commercial products resistant fungal strains was validate, principally against dermatophytes fungi 46 
such as T. rubrum, T. mentagrophytes, M. canis, and M. gypseum. These results indicate that the 47 
hydroalcoholic preparations could be used for the treatment of fungal infectious. 48 
Keywords: Baccharis tola, Baccharis boliviensis, Argentine Puna, Antifungal activity, 49 
Dermatophytes. 50 
51 
Introduction  52 
In recent years, there was a notable increase in the frequency and severity of fungal infections, 53 
caused not only by agents already known but by emerging pathogens, until recently considered 54 
non-pathogens or laboratory contaminants. This is justified by many reasons, the most important 55 
being the increase in patients with risk pathologies, such as cancer with induced neutropenia, 56 
transplanted patients submitted to immunosuppressiv therapies or patients with HIV (Armstrong-57 
James et al., 2014; Bongomin et al., 2017; Chapman et al., 2017; Sowmya et al., 2015). Other 58 
predisposing factors for opportunistic human mycoses are nutritional factors, and the abuse of 59 
drugs such as broad-spectrum antibiotics, corticoster ids, and immunosuppressants (Denning and 60 
Bromley, 2015; Roemer and Krysan, 2014).  61 
The high rates of morbidity and mortality caused by fungal infections are associated with the 62 
current limited antifungal arsenal and the high toxicity of the available drugs (Scorzoni et al., 63 
2017). On the other hand, some fungi of clinical importance present natural resistance to antifungal 64 
agents. In some cases, resistance is not innate but acq ired as a result of previous antifungal 65 
therapy (Khosravi et al., 2018). For this reason, new antifungal agents are being sought. It has been 66 
demonstrated that medicinal plants are an important source of new biologically active compounds 67 
with antimicrobial activity (antibacterial and antifungal) as well as anti-inflammatory, among other 68 
properties with possible therapeutic effects (Abu-Darwish et al., 2013; Di Ciaccio et al., 2018; 69 
Mesa Arango et al., 2004; Moreno et al., 2018a, b, c; Nuño et al., 2014;  Palavecino Ruiz et al., 70 
2016; Salhi et al., 2017; Sayago et al., 2012; Torres-Carro et al., 2015, 2017; Zacchino et al., 2003; 71 
Zampini et al., 2009b, 2012).  72 
The Andes highlands, known as Puna, extends throughout southern Peru, west of Bolivia, north of 73 
Chile and northwest of Argentina at altitudes ranging from 3300 to 5000 meters above sea level 74 
(masl). The Argentine Puna comprises part of Jujuy, Salta, Tucumán, Catamarca, La Rioja and San 75 
Juan provinces, in an altitudinal level ranging between 2600 and 4800 masl (Figure 1). This area is 76 
characterized by scarce rainfall during the year, low atmospheric pressure and high UV radiation 77 
and extreme temperature conditions (Cabrera, 1968). The species that live in these ecosystems 78 
develop adaptation mechanisms to survive such as morphoanatomic changes as well as the 79 
production of secondary metabolites against abiotic s ress. Baccharis species belong to the 80 
Asteraceae family, some of those that grow in the Argentine Puna, such as B. boliviensis and B. 81 
tola (Figure 2), are frequently used by local people in traditional medicine as infusion, decoction 82 
and ethanol maceration of the aerial parts to treat skin infections (wounds, burns and ulcers), as 83 
anti-inflammatory and as gastric protective agents (Abad Martinez et al., 2005; Abad and Bermejo, 84 
2007; Calle et al., 2017; Torres-Carro et al., 2017; Villagrán et al., 2003; Zampini et al., 2009a, 85 
2009b). Some of their medicinal properties have been validated for both Baccharis species: 86 
antibacterial activity against Gram-positive and Gram-negative antibiotic-resistant bacteria (Nuño 87 
et al., 2012; Zampini et al., 2009a, 2009b), antioxidant activity (Nuño et al., 2012; Zampini et al., 88 
2008) and anti-inflammatory activity (Alberto et al., 2009; Torres-Carro et al., 2015). As well, 89 
some terpenoid and phenolic compounds were identifid n B. boliviensis (Abad Martinez et al., 90 
2005; Calle et al., 2012; Cazón et al., 2002; Zdero et al., 1989) and B. tola (Abad Martinez et al., 91 
2005; Desmarchelier et al., 2000; Faini et al., 1982; Givovich et al., 1986; San Martín et al., 1980, 92 
Simirgiotis et al., 2016; Zampini et al., 2009a). Nevertheless, a survey of the literature revealed 93 
that there are no studies on the validation of the antifungal capacity of these plants.  94 
In the present investigation, the activity of phytotherapeutic preparation of B. boliviensis and B. 95 
tola from Argentine Puna was studied against clinically relevant fungi (yeast, non-dermatophytes, 96 
and dermatophytes). Chemical characterization of both phytotherapeutic preparations was also 97 
included in the study.  98 
 99 
2. Material and Methods 100 
2.1 Plant material 101 
Baccharis boliviensis (Wedd.) Cabrera var. boliviensis and Baccharis tola Phil. ssp. tola were 102 
collected during the month of February 2018 in Antofagasta de la Sierra, Catamarca, Argentina, at 103 
3800 masl (Figure 1). The plants were identified by Dra. Ana Soledad Cuello, INBIOFIV 104 
(CONICET) and voucher specimens were included in the Herbarium of Fundación Miguel Lillo, 105 
San Miguel de Tucumán, Tucumán, Argentina (B. boliviensis, 607936 LIL, B. tola, 607934 LIL).  106 
2.2 Phytotherapeutic preparation of Baccharis 107 
Aerial parts of plant material were dried, grounded, and macerated in a hydroalcoholic solution (10 108 
g dry tissue in 100 mL of 80% ethanol) for 7 days at room temperature. The extracts were passed 109 
through filter paper Whatman N°.1 to remove plant debris. The extracts were concentrated “in 110 
vacuo” at 40 °C, and then freeze-dried. The dry extracts were stored at −20 °C, until use. 111 
2.3 Phytochemical analysis 112 
2.3.1. Determination of total phenolic and flavonoid contents 113 
Total phenolic compounds content was determined by the Folin–Ciocalteu method (Singleton et 114 
al., 1999). Results were expressed as µg of gallic acid equivalents (GAE) per mL (µg GAE/mL). 115 
Total flavonoids were estimated using the method of W isky and Salatino, (1998). Results were 116 
expressed as µg of quercetin equivalents (QE) per mL (µg QE/mL). 117 
2.3.2. UHPLC-PDA-MS Instrument. 118 
A Thermo Ultimate 3000 UHPLC system connected to a Thermo Q exactive focus used in this 119 
study allowed a rapid separation with photodiode (PDA) detection and high flow rates (0.8 mL per 120 
min), zero dead volume with viper technology, using effective negative electrospray ionization of 121 
the improved heated electrospray probe (HESI II), and thus getting ultrahigh resolving power 122 
performance with selectivity of a quadrupole and the orbital trap (70,000 FWHM at m/z 200), and 123 
the outstanding diagnostic power of a high resolutin collision (HCD) cell. For the analysis 10 mg 124 
of the extract were dissolved in 2 mL of methanol, filtered (PTFE filter, 200 microns) and 15 µL 125 
were injected in the instrument, with all specificat ons set as previously reported (Simirgiotis et al., 126 
2016). 127 
2.3.3. LC-MS parameters. 128 
Liquid chromatography was performed using a C-18 column (HPLC-Acclaim, 2.5 µm, 150 mm × 129 
4.6 mm ID, Thermo, Bremen, Germany) operated at 25 ◦C. The detection wavelengths were 330, 130 
254, 280, and 354 nm, and photodiode array was record d between 800-200 nm for UV 131 
characterization. Mobile phases were 1 % formic aqueous solution (A) and acetonitrile (B). The 132 
gradient program (time (min), % B) was: (0.00 min, 3% B); (5.00 min, 3% B); (10.00 min., 20% 133 
B); (15.00 min, 20% B); (20.00 min, 45% B); (25.00 min, 65% B); (35.00 min, 3% B) and 15 min 134 
for column equilibration before each injection. The flow rate was 0.8 mL.min−1, and the injection 135 
volume was 15 µL. Standards and the resin extract dissolved in methanol were kept at 20 ◦C during 136 
storage in the autosampler. The HESI II and Orbitrap spectrometer parameters were optimized as 137 
previously reported (Simirgiotis et al., 2016). 138 
2.4 Fungal strains 139 
In this study were included clinical isolated of yeasts (n=25) and filamentous fungi [non-140 
dermatophytes (n=9) and dermatophytes (n=10)] and two s andard strains from the American Type 141 
Culture Collection (ATCC), Candida (C.) albicans ATCC 64548 and C. glabrata ATCC 90030. 142 
Yeasts strains: C. albicans (n=7), C. tropicalis (n=1), C. guilliermondii (n=3), C. glabrata (n=1), 143 
C. dubliniensis (n=1), Candida spp. (n=10), and Saccharomyces (S.) cerevisiae (n=2).   144 
Non-dermatophyte filamentous fungi strains: Aspergillus (A.) niger (n=1), A. clavatus (n=1), 145 
Penicillium (P.) islandicum (n=1), Penicillium spp. (n=1), Absidia (A.) orchidis (n=1), Mucor spp. 146 
(n=1), Rhizopus spp. (n=1), Alternaria spp. (n=1), Scopulariopsis (S.) brevicaulis (n=1). 147 
Dermatophyte filamentous fungi strains: Trichophyton (T.) rubrum (n=7); T. mentagrophytes 148 
(n=1), Microsporum (M.) gypseum (n=1) and M. canis (n=1). 149 
Strains of yeasts and non-dermatophyte filamentous fungi, were obtained from the Servicio de 150 
Diagnóstico de la Cátedra de Micología, Facultad de Bioquímica, Química y Farmacia, 151 
Universidad Nacional de Tucumán, Argentina; and the dermatophytes strains were obtained from 152 
the Servicio de Micología del Hospital Centro de Salud “Zenón Santillán” de San Miguel de 153 
Tucumán, Argentina. 154 
The different clinical specimens were cultured on Sabouraud agar supplemented with 155 
chloramphenicol (0.05 g/L) (SA-Cl). All the strains were maintained in distilled water (Castellani, 156 
1939; Castellani, 1963) and sub-cultured in SA-Cl every 15 days to prevent pleomorphic 157 
transformations.  158 
2.5 Determination of Minimal Inhibitory Concentration (MIC) 159 
MIC was defined as the lowest concentration of extracts capable to produce the total inhibition of 160 
the growth of fungi after incubation time. It was determined by two methods:  161 
a) Macrodilution method in agar according to Derita e  al., 2007 with some modifications. Briefly, 162 
stock solutions of extracts, diluted in ethanol 80% were added to the medium SA-Cl to give serial 163 
two-fold dilutions, resulting in concentrations rangi g from 25 to 800 µg GAE/mL. The inoculum 164 
(2 µL) containing 5x104 CFU/mL was spouted on top of the SA-Cl agar. Sterili y control (no 165 
inoculum added), inoculum viability (no extract adde ), and solvent control (ethanol 80%), and 166 
positive control (Ketoconazole) were carried out. 167 
Plates were incubated at 28 °C for 48 h for the case of yeasts, 72 h for non-dermatophyte 168 
filamentous fungi and 5 days for the dermatophytes s rains. After incubation, fungal growth was 169 
evidenced by the presence of mycelium or visible colonies in the agar. For the resistent non-170 
dermatophyte strains, the colony diameter (mm) was measured at 3, 7 and 10 days of development 171 
and the percentage inhibition of diameter growth (% IN) (Rosas-Burgos et al., 2009) was obtained 172 
according to the following formula: 173 
        % IN= [(C – E)/ C] X 100 174 
where: 175 
                C = growth diameter in solvent contr l plate 176 
                E = growth diameter in a plate with extract 177 
b) Microdilution method were based on the CLSI refer nce protocols M27-A3 (CLSI 2008a) and 178 
M38-A2 (CLSI 2008b), for yeasts and filamentous fungi, respectively. For the assay, stock 179 
solutions of extracts were two-fold diluted with medium SA-Cl (25 to 400 µg GAE/mL). A 180 
volume of 100 µL of inoculum suspension (4x103 CFU/mL) was added to each well. 181 
Sterility, inoculum viability, solvent, and positive (Fluconazole) controls were included. Plates 182 
were incubated at 28 °C for 48 h for the case of yeasts, 72 h for non-dermatophyte filamentous 183 
fungi and 5 days for the dermatophytes strains. After incubation, fungal growth was evidenced by 184 
the presence of turbidity or a pellet on the well. The microdilution method was also used to 185 
determine MFC values.  186 
2.6 Determination of minimal fungicidal concentrations (MFC)  187 
MFC was defined as the lowest concentration of extracts capable to produce the irreversible 188 
inhibition of the viability of fungi after incubation time. To determine MFC values, after reading 189 
the corresponding MIC values, 10 µL of each well without visible growth were subcultured on SA-190 
Cl plates. The plates were incubated at 28 °C for 48hs for the yeasts and 5 days for dermatophytes 191 
fungi. The MFC values were determined as the lowest concentration of extracts where no visible 192 
growth was observed after incubation (Chellappandian et al., 2018). 193 
All antifungal assays were tested in triplicate. 194 
 195 
3. Results and discussion 196 
3.1. Phytochemical analysis 197 
In this work, a phytochemical study of B. boliviensis and B. tola hydroalcoholic extracts was 198 
conducted in order to obtain a standardized phytotherapeutic preparation of each plant species. B. 199 
boliviensis showed higher total phenolic and total flavonoids content than B. tola extract (Table 1). 200 
These results are in agreement with previous reports in hese plant species collected in argentine 201 
Puna (Alberto et al., 2009; Sayago et al., 2012; Torres-Carro et al., 2015; Zampini et al., 2008). 202 
Calle et al., (2017) has reported similar content of total flavonoids in both plant species collected 203 
in Bolivia at 3600 masl.  204 
The chromatographic patterns by UHPLC-MS of phytotherapeutic preparations of two Baccharis 205 
species were similar, both species present common chemi al compounds (Figure 3, Table 2). 206 
Several compounds including terpenoids, flavonoids and phenolic acids have been identified in 207 
these two endemic South American Baccharis species for the first time (Table 2) using and 208 
orbitrap high resolution instrument. Some of the idntified compounds have been previously 209 
identified and isolated. The detailed identification s explained above:  210 
Phenolic and other organic acids 211 
Peak 1 with a [M-H]- ion at m/z: 195.05072 was tentatively identified as gluconic acid (C6H12O7
-), 212 
peak 2 with a [M-H]- ion at m/z: 191.01956 as quinic acid (C6H7O7
-) and peaks 4 and 7 with a 213 
parent molecule at m/z: 367.10373 and 367.10376 producing fragments at m/z: 191.05573, and 214 
134.03664 identified as feruloyl-quinic acids (C17H19O9
-), the same case is peak 5 which was 215 
appointed as chlorogenic acid (C17H17O9
-), moreover, peaks 13-15 were identified as isomers of  216 
dicaffeoyl-quinic acid (C25H23O12
-), (Simirgiotis et al., 2015), while peak 16 with a deprotonated 217 
molecule at m/z: 529.13519 was identified as 1-caffeoyl-5-feruloylquinic acid (C26H25O12
-), 218 
finally, peak 27 was identified as syringaresinol (C22H25O8
-) (Simirgiotis et al., 2016). 219 
Flavonoids  220 
Several compounds were identified as flavonols (UV max around 255-355 nm) others as 221 
flavanones (UV max at around 280 nm). Consequently, peak 6 with a [M-H]- ion at m/z: 222 
593.15204 and producing a kaempferol ion at m/z:  285.05062 was identified as kaempferol-3-O- 223 
rutinoside (C27H29O15
-). Peak 9 with a deprotonated molecule at m/z: 317.06656 was identified 3-224 
hydroxy-hesperetin (C16H13O7
-), peak 10-12 were identified as myricetin 7,3'-dimethyl ether 225 
(C17H13O8
-), isorhamnetin (C16H11O7
-) and palulitrin (C22H21O13
-), while peaks 17, 18, 20, 21 and 226 
23 were appointed as 8-prenyl-3-hydroxy-eriodictyol, 3-O-methyl-luteolin, eriodictyol, rhamnetin, 227 
and quercetin, respectively. Peaks 22, 26, 30, 32 and 36, with pseudomolecular ions at m/z: 228 
389.08787, 373.09286, 375.07216, 359.07703 and 389.08 32, and all producing myricetin 229 
fragment daughter ions at m/z: 317.03026 (C15H9O8
-), were identified as myricetin 6-hydroxy-3, 230 
7,3',5'-tetramethyl ether, myricetin 8-methyl-7,3',5'-trimethyl ether, myricetin 6-hydroxy-7,3',5'-231 
trimethyl ether, myricetin 7,3',5'-trimethyl ether and myricetin-6,7,3',5'-tetramethyl ether, 232 
respectively; some of those compounds have been previously isolated (Zampini et al., 2009a). 233 
Peak 28 was identified as the acetyl derivative of myricetin. In the same manner, peak 19, 24 and 234 
31, producing isorhamnetin ions at m/z:  315.05102 (C16H11O7
-), were identified as the 3-O-methyl 235 
and 7-O-methyl ether of isorhamnetin, and the 3,7-di-O-methyl ether derivative, respectively, 236 
methoxylated compounds coincident with those isolated previously (Zampini et al., 2009a). Peak 237 
25 with at m/z: 345.06186 was identified as syringetin (C17H13O8
-), peak 44 was identified as 238 
5,7,3',4'-tetrahydroxy-6-methoxyflavanone; filifolin, and peak 43 at m/z: 375.07670 was identified 239 
as limocitrol (C18H15O9
-). MS spectra and structures of some methoxylated flavones detected in 240 
Baccharis species are shown in Figure 4 and Figure S1. 241 
Diterpenoids 242 
Peak 34 with a pseudomolecular ion at m/z: 301.1807 was identified as the clerodane diterpenoid 243 
solidagoiol A (C20H29O2
-), (Simirgiotis et al., 2016) a reduction derivative of solidagoic acid A 244 
(MW: 315.1966, C20H27O3
-, not detected) while peak 29 with a pseudomolecular ion at m/z:  245 
373.20205 as 19-acetoxy-solidagoic acid A ( C22H29O5
-), peak 33 as 19-hydroxy-solidagoiol A, 246 
and peak 35 with a [M-H]- ion at m/z: 359.22276 as 19-O-acetyl-soligagoiol A (C22H31O4
-), and 247 
peak 45 as 3,4 dihydro-19-acetoxy-solidagoic acid A (C22H31O5
-), (Simirgiotis et al., 2016) while 248 
peak 37 was identified as hawtriwaic acid (C20H27O4
-) (Simirgiotis et al., 2000)  and peaks 47 and 249 
48 with pseudomolecular ions at m/z: 287.20142 (C0H31O
-) were identified as ent-Beyer-15-en-250 
18-ol compounds previously reported in B. tola (Parra et al., 2015; San Martín et al., 251 
1980;Simirgiotis et al., 2016). Peaks 38 and 39, with pseudomolecular ions at m/z: 433.23345 and 252 
433.22263 Daltons were identified as the isomers: 17-O-succynyl-3,7-dihydroxy-ent-cleroda-253 
1,13(16),14-triene-15,16-oxide, and 17-O-succynyl-3,4-dihydroxy-ent-cleroda-1,13(16),14-triene-254 
15,16-oxide (C24H33O7
-) (Zdero et al., 1989), in the same manner peaks 40 and 41 were identified 255 
as 17-O-succynyl-3-hydroxy-ent-cleroda-1,13(16),14-triene-15,16-oxide and 17-O-succynyl-4-256 
hydroxy-ent-cleroda-1,13(16),14-triene-15,16-oxide, and peak 42 as 17-O-succynyl-3,4,7-257 
trihydroxy-ent-cleroda-1,13(16),14-triene-15,16-oxide (C24H33O8) while peak 46 was identified as 258 
17-O-succynyl-ent-cleroda-1,13(16),14-triene-15,16-oxide and finally peak 49 as 17-O-succynyl-259 
ent-cleroda-1,13(16),14-triene-15,16-oxide (C26H37O7
-). Some of those compounds were 260 
previously isolated from B. boliviensis (Zdero et al., 1989). MS spectra and structures of some 261 
clerodanes detected in Baccharis species are shown in Figure S1 262 
Other compounds 263 
Peak 3 with a [M-H]- ion at m/z: 205.07159 as diethyl tartrate (C8H14O6
-), Peak 8 was identified as 264 
barlerin (C19H27O12
-), Peak 52 at m/z: 289.11185 was identified as the coumarin sibiricin 265 
(C16H17O5
-), peaks 50 and 51 with ions at m/z: 325.18453 and 339.20023 were tentatively 266 
identified as  heptaethylene glycol and  heptaethylne glycol methyl ether, respectively. 267 
3.2. Antifungal activity of Baccharis extracts   268 
Phytotherapeutic preparations were tested against a panel of fungal strains which included yeasts 269 
(Candida spp. and Saccharomyces cerevisiae) and filamentous fungi (non- dermatophytes and 270 
dermatophytes) which were selected for their clinical relevance. C. albicans and C. tropicalis were 271 
selected due to their high incidence of candidemia ( ore than 80%) in Latin America (Nucci et al., 272 
2013). C. glabrata has been identified as the second leading cause of adult candidemia particularly 273 
in patients with hematologic malignancies (Pfaller and Diekema, 2007). Among filamentous fungi, 274 
Fusarium spp., Aspergillus spp., and S. brevicaulis are the most commonly recovered in 275 
opportunistic mycoses following Candida spp. (Babayani et al., 2018). Cutaneous fungal 276 
infections are among the most common fungal infections and are mainly caused by keratinophilic 277 
filamentous fungi (dermatophytes), that use keratin s a nutrient in skin, hair and nail infections 278 
(Massiha and Muradoy, 2015). Dermatophyte fungi included T. rubrum, T. mentagrophytes, M. 279 
gypseum and M. canis due to their high incidence in superficial fungal infections (Ayatollahi 280 
Mousavi and Kazemi, 2015). Species of Trichophyton account for as many as 70% of all 281 
dermatophyte infections (Jarabrán et al., 2015; Mukherjee et al., 2003); M. gypseum, although 282 
saprophytic in immunocompetent individuals, produces important infections in 283 
immunocompromised patients due to its keratinolytic potential (Tambekar et al., 2007). 284 
The in vitro antifungal assay (MIC and MFC values) of ethanolic extracts of B. boliviensis and B. 285 
tola was performed using macrodilution and microdilution methods. The results revealed that in 286 
general, the assayed dermatophyte isolates, were mor  sensitive to the preparation of B. boliviensis  287 
than to that of B. tola. Moreover, C. guilliermondii, C. dubliniensis, and S. cerevisiae were the 288 
species most sensitive to both phytotherapeutic preparations, with MIC values between 50 and 200 289 
µg GAE/mL for B. boliviensis, and between 200 and 400 µg GAE/mL for B. tola (Table 3). Within 290 
the filamentous fungi, the viability of non-dermatophyte fungi were not affected by the 291 
preparations while the dermatophyte fungi strains were the most sensitive isolates to both extracts; 292 
thereby 100% of the strains were inhibited by B. boliviensis preparation with MIC values between 293 
25 and 200 µg GAE/mL and MFC values between 50 and 400 µg GAE/mL whereas that of B. tola 294 
inhibited the 80% of the strains with MIC values betw en 100 and 400 µg GAE/mL and MFC 295 
values between 200 and 400 µg GAE/mL. T. rubrum isolates were the most sensitive strains 296 
(Table 3). These results are interesting, considering that T. rubrum is the etiological agent of 80–297 
93% of all clinical infections produced by dermatophytes. Moreover, all dermatophytes strains 298 
were resistant to fluconazole (positive control), with MIC values > 128 µg/mL; it has been 299 
reported that certain strains of dermatophytes are resistant to fluconazole (Méndez-Tovar, et al., 300 
2007; Santos and Hamdan, 2006). In general, the most frequently systemic antifungal agents used 301 
for dermatophytosis treatment are fluconazole, terbinafine, and itraconazole, with prolonged 302 
schedules, risk of drug interactions and high associated costs, which hinder adherence to treatment; 303 
in most cases the success obtained with the treatment us d is low and it may be due to multiple 304 
factors, including the resistance of isolated fungi to the medications used (Gupta et al., 2001).  305 
Furthermore, the percentage inhibition of diameter growth (% IN) produced by each extract was 306 
determined against the non-dermatophyte strains that were resistant to the extracts in the highest 307 
tested concentration (800 µg GAE/mL) in order to find out the effect of each extract on the 308 
mycelium growth. Table 4 shows the results obtained with 3200 µg GAE/mL. S. brevicaulis was 309 
the strain more inhibited by the hydroalcoholic extrac s, showing 100% inhibition with B. 310 
boliviensis after ten days of incubation while B. tola inhibit the growth up to seven days, and after 311 
ten days of incubation just 10% of growth was observed. A. orchidis, Alternaria spp. and Mucor 312 
spp. showed also a strong inhibition by both extracts. A. niger, A. clavatus and P. islandicum were 313 
the more resistant strains (Table 4). In Figure 5 a representative photo of the filamentous fungi 314 
growth inhibition produced by the hydroalcoholic extracts of B. boliviensis and B. tola is shown. 315 
The presence of several identified compounds in this work would support the Baccharis extracts 316 
antifungal activity. Several flavonoids identified have been regarded as antifungal agents (Afifi et 317 
al., 1991; Candiracci et al., 2011; Santos and Pereira, 2018; Weidenbörner and Jha, 1997) in 318 
particular, some methylated flavones (Figure 4 and Figure S1) could be of particular attention due 319 
to more liposolubility (Meragelman et al., 2005). On the other hand, clerodanes diterpenes are 320 
bioactive compounds isolated from several plant species with several biological properties 321 
reported, including antifungal activity (Li et al., 2016). For instance, three neo-clerodane 322 
diterpenoids, jodrellin A, jodrellin B and clerodin solated from Scutellaria showed antifungal 323 
activity against the pathogenic fungi Fusarium oxysporum f. sp. lycopersici and Verticillium 324 
tricorpus (Cole et al., 1991). According the analysis of UHPLC-OT-MS metabolome 325 
fingerprinting, some ent-clerodanes are present in B. boliviensis extract (peak 40, 41 and 42) but 326 
not in B. tola which could be related to the greater antifungal activity of B. boliviensis. Regarding 327 
ent-clerodane terpenoids from Baccharis and antifungal activity, also some ent-clerodanes 328 
demonstrated antifungal activity in a synergistic manner combined with antifungal drugs such as 329 
terbinafine (Rodriguez et al., 2013, Rodriguez et al., 2019).  330 
Previous studies performed with ethanolic extract of B. boliviensis from Monte region of 331 
Argentina (Mendoza province, at 1890 masl), did notdemonstrated antifungal activity against 332 
yeast (C. albicans, C. tropicalis, Cryptococcus neoformans, S. cerevisiae), filamentous fungi (A. 333 
fumigatus, A. flavus, A. niger) nor dermatophytes (M. gypseum, T. rubrum, T. mentagrophytes and 334 
Epidermophyton floccosum) at a concentration of 1000 µg/mL (Svetaz et al., 2010). Probably the 335 
chemical composition of plants collected in different co-regions from Argentina (Monte region vs 336 
Puna region) presents some differences. However, th chemical composition of B. boliviensis 337 
extract from Mendoza province was not reported until now. Ethanolic extracts of other plant 338 
species from the extremophile region of the Puna (Chuquiraga atacamensis, Parastrephia 339 
phyliciformis, Parastrephia lepidophylla nd Tetraglochin andina) presented antifungal activity on 340 
mycelial phytopathogenic fungi and vaginal yeast species (with MIC values of 250-500 µg 341 
GAE/mL) (Moreno et al., 2018a; Palavecino Ruiz et al., 2016; Sayago et al., 2012). 342 
Other Baccharis species that growth in Argentina such as B. darwinii and B. articulate showed 343 
activity against dermatophytes fungi (T. rubrum, T. mentagrophytes and M. gypseum) with MIC 344 
values of 250-500 µg/mL and MFC values of 100-500 µg/mL, but did not present activity (MIC > 345 
1000 µg/mL) against yeasts and/or non-dermatophyte fungi (C. albicans, C. tropicalis, S. 346 
cerevisiae, Cryptococcus neoformans, A. flavus, A. fumigatus, A. niger) (Kurdelas et al., 2010; 347 
Vivot et al., 2009). On the other hand, other authors reported that B. pingraea, B. medullosa, B. 348 
notosergila, B. polifolia, B. stenophylla, B. articulate, B. crispa, B. gaudichaudiana, B. 349 
microcephala, B. penningtonii, B. phyteumoides, B. sagittalis, B. triangularis, B. trimera and B. 350 
grisebachii, did not present activity against dermatophytes, yeasts and/or filamentous fungi (C. 351 
albicans, C. tropicalis, C. neoformans, S. cerevisiae, A. fumigatus, A. flavus, A. niger, M. gypseum, 352 
T. rubrum, T. mentagrophytes, E. floccosum), up to 1000 µg/mL (Feresin et al., 2001; Rodriguez et 353 
al., 2013; Svetaz et al., 2010). 354 
Rosas-Burgos et al. (2009) reported the effect of methanolic extract of Baccharis glutinosa (8.4 355 
mg/mL) against filamentous fungi (A. flavus, A. parasiticus, and F. verticillioides) with an 356 
inhibition of no more than 60% after 14 days of incubation. 357 
4. Conclusion 358 
The phytotherapeutic preparations obtained with aerial parts of B. tola and B. boliviensis, two 359 
shrubs growing in the Puna, are used popularly to treat skin and soft tissue infections by topical 360 
application. The results indicate that the hydroalcholic preparations obtained from aerial parts of 361 
B. boliviensis and B. tola could be used for the treatment of infectious skin disease produced by 362 
fungi, principally those caused by dermatophytes, the most common responsible of infectious skin 363 
disease that requires a long time treatment.  Fifty-two compounds including several terpenoids and 364 
poly-hydroxilated and methylated flavonoids were accurately identified from B. boliviensis and B. 365 
tola for the first time, and several of identified compounds are regarded as antifungal agents. 366 
Further investigations are being carried out in our laboratory to isolate and characterize the active 367 
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604 
Figure legends 605 
Figure 1. Map of the Argentine Puna, the collection site of plants (Antofagasta de la Sierra, 606 
Catamarca, Argentina). 607 
 608 
Figure 2. Photography of plants species: A) and B) B. boliviensis; C) and D) B. tola. 609 
 610 
Figure 3. UHPLC-MS Chromatograms of a) B. boliviensis extract (Base peak, negative mode) and 611 
b) B. tola extract (Base peak, negative mode).  612 
 613 
Figure 4. Examples of methoxylated flavones detected in Baccharis species  614 
 615 
Figure 5. Representative photo of radial growth inhibition of filamentous fungi at 7 days of 616 
development. A) Mucor spp. B) Absidia orchidis. C) Alternaria spp. D) Penicillium spp. 1) 617 
Solvent control (80% ethanol), 2) B. boliviensis hydroalcoholic extract (3200 µg GAE/mL). 3) B. 618 
tola hydroalcoholic extract (3200 µg GAE/mL).   619 
 620 
Fig. S1. Examples of methoxylated flavones and clerodanes detected in Baccharis species. Full 621 
MS spectra and structures of compounds 10, 30, 38, 42, 44 and 46. 622 









Table. 2. High resolution UHPLC-PDA-MS metabolite profiling data of the phytotherapeutic preparation of Baccharis boliviensis and 




Total  flavonoids  
(µg QE/mL) 
B. boliviensis 3780.6 ± 19.6 1354.5 ± 131.9 








Tentative identification Elemental 
composition 



















195.04993 195.05072 0.22  a,b 





191.01863 191.01956 4.88  b 





205.07066 205.07159 4.53  b 
4 11.32 210 Feruloyl-quinic acid  C17H19O9
- 367.10236 367.10373 3.73 191.05573, 134.03664 a   
5 11.96  Chlorogenic acid*  C17H17O9
- 356.08671 
 




6 12.50 265-365 Kaempferol-3-O- rutinoside  C27H29O15
- 593.15010 
 
593.15204 4.38 285.05062 (C15H9O6
-) a,b 
7 12.63 210 Feruloylquinic acid C17H19O9
- 367.10236 367.10376 3.81 191.05577, 134.03664 a,b   
8 12.95 210 Barlerin C19H27O12
- 447.14970 447.15118 3.31     
9 13.25 285 3-Hydroxy-hesperetin  C16H13O7
- 317.06668 317.06656 0.31 302.04291 (C15H10O7
-) a,b 
10 13.50 277-353 Myricetin 7,3'-dimethyl ether  C17H13O8
- 345.0616 345.06152 0.28 330.0377, 315.01445  b 
11 13.75 252-352 Isorhamnetin*  C16H11O7
- 315.05090 315.05103 -0.3 301.03535, 179.03342, 
151.05463 
a b 
12 13.96 252-352 Palulitrin  C22H21O13
- 493.09767 493.09909 2.88  a,b 
13 14.27 213, 287, 
326 
1,3- Di-O-caffeoyl quinic acid C25H23O12
- 515.11840 515.11975 2.61 191.05585 a   
14 14.47 213, 287, 
326 
1,4- Di-O-caffeoyl quinic acid C25H23O12
- 515.11840 515.11969 2.49 191.055853 a,b   
15 14.88 213, 287, 
326 
1,5- Di-O-caffeoyl quinic acid C25H23O12
- 515.11840 515.11987 2.85 191.055852 a,b   




- 529.13405 529.13519 2.15 191.05577 (quinic acid), 
134.03664 
a,b 
17 16.05 286-325 8-Prenyl-3-hydroxy-eriodictyol C20H19O7
- 371.11363 371.11331 0.80 239.10718 (C16H15O2-) a,b   
18 17.04 254-354 3-O-Methyl-luteolin C16H11O6
- 299.05611 299.05591 0.66 284.03220 (C15H8O6
-) a 
19 17.27 252-352 Isorhamnetin 3-methyl ether C17H13O7






20 17.95 280 Eriodictyol* C15H12O6
- 287.05501 287.05643 4.94 179.05342 a,b 
21 18.02 254-355 Rhamnetin C16H11O7


























4.84 271.83310, 177.09688 a,b 
24 19.72 252-352 Isorhamnetin 7-methyl ether C17H13O7





25 21.37 252-352 Syringetin  C17H13O8
- 345.06234 345.06186 3.51 301.03528, 179.03342, 
151.05476 
a,b 










27 21.63 248-272sh Syringaresinol  C22H25O8
- 
 
417.15553 417.11895 8.77 407.0903, 371.1135 [M-
H-HCOOH]- 
a,b 
28 21.75 277-353 3-Acetyl-myricetin C17H11O9
- 359.04086 359.04047 1.11 317.03026 (C15H9O8
-) b 
29 21.86 205 19-Acetoxy-solidagoic acid A  C22H29O5
- 373.20192 373.20205 1.21   
30 21.97 277-353 Myricetin 6-hydroxy-7,3',5'-
trimethyl ether 
C18H15O9




a,b   
31 22.12 252-352 Isorhamnetin 3,7-di-methyl ether C18H15O7




a,b   
32 22.56 
 
277-353 Myricetin 7,3',5'-trimethyl ether C18H15O8
- 
 




a,b   
33 22.67 205 19-Hydroxy-Solidagoiol A  C20H29O3
- 317.21224 317.21204 0.63  a,b   
34 23.12 203 Solidagoiol A  C20H29O2
- 301.21738 301.18073 10.52  b   
35 23.43 203 19-O-acetyl-soligagoiol A  C22H31O4
- 359.22287 359.22276 0.27  b 
36  
23.87 














37 23.62 204 Hawtriwaic acid  C20H27O4








- 433.22208 433.23345 1.26  a,b 




- 433.22208 433.22263 3.16  a,b   




- 417.22717 417.22864 3.52  a   










- 417.22717 417.22867 3.60  a   




- 449.21699 449.21857 3.52  a   
43 24.92 254 356 Limocitrol  C18H15O9
- 375.07673 375.07670 2.12 258.17055, 179.05436  b   
44 25.40 254-355 5,7,3',4'-tetrahydroxy-6-
methoxyflavanone; Filifolin 
C16H13O7
- 317.06558 317.06689 4.14  a   
45 25.93 205 3,4 Dihydro-19-acetoxy-solidagoic 
acid A  
C22H31O5






a   
46 26.25 220 17-O-succynyl-ent-cleroda-
1,13(16),14-triene-15,16-oxide 
C24H33O5
- 401.23225 401.23380 3.84  a,b   
47 26.42 - ent-Beyer-15-en-18-ol C20H31O
- 287.23805 287.20142 12.7  a,b   
48 26.76 - ent-Beyer-15-en-19-ol C20H31O
- 287.23806 287.20153 12.8  a   




- 461.25338 461.25497 3.45  a   
50 28.23 - Heptaethylene glycol C14H3OO8
- 325.18569 325.18453 -3.52  a   
51 28.45 - Heptaethylene glycol methyl ether C15H31O8
- 339.20134 339.20023 -3.22  a,b   
52 29.10 270-310 Sibiricin  C16H17O5
- 289.11292 289.11185 -3.7  a   
Table 3: MIC, MFC values of the hydroalcoholic extracts and MIC values of ketoconazole or fluconazole.  
Strains 
 






(µg/mL) B. boliviensis B. tola B. boliviensis B. tola 
        Yeasts      
C. albicans A1  R R R R 2 
C. albicans A2 R R R R 8 
C. albicans A3 800 R R R 0.12 
C. albicans A4 R R R R 2 
C. albicans A5 R R R R 8 
C. albicans A6 R R R R 0.12 
C. albicans A7 R R R R 0.5 
C. glabrata B1 R R R R 16 
C. guilliermondii C1 100 400 100/R 400/R 0.03 
C. guilliermondii C2 50 400 50/R 400/R 0.03 
C. guilliermondii C3 800 R R R 0.12 
C. tropicalis D1 R R R R 4 
C. dubliniensis E1 100 800 100/R R - 
Candida spp. F1 R R R R 0.12 
Candida spp. F2 R R R R 0.06 
Candida spp. F3 R R R R 0.06 
Candida spp. F4 R R R R 2 
Candida spp. F5 R R R R 16 
Candida spp. F6 R R R R 0.5 
Candida spp. F7 R R R R 0.5 
Candida spp. F8 R R R R 0.5 
Candida spp. F9 R R R R 0.5 
Candida spp. F10 R R R R 0.5 
S. cerevisiae G1 200 200 200/R 200/R 16 
S. cerevisiae G2 800 800 R R 1 
C. albicans ATCC 64548          R R R R 8 
C. glabrata ATCC 90030  R R R R 4 
Dermatophytes     Fluconazole 
T. rubrum 014 100 400 100/100 400/400 ˃ 128 
T. rubrum 006 100 400 100/100 400/400 ˃ 128 
T. rubrum 067 100 200 100/100 200/200 ˃ 128 
T. rubrum 020 25 100 25/50 100/200 ˃ 128 
T. rubrum 105 200 200 200/200 200/R ˃ 128 
T. rubrum 102  50 200 50/200 200/400 ˃ 128 
















            -: not tested 


















T. mentagrophytes 200 800 200/400 R   ˃ 128 
M. gypseum 200 800 200/200 R  ˃ 128 
M. canis 108 100 200 100/100 200/R ˃ 128 
Non-dermatophytes     Ketoconazole 
A. niger R  R R R - 
A. clavatus R R R R - 
Penicillium spp. R R R R - 
P. islandicum R R R R -  
A. orchidis R R R R 4 
Mucor spp. R R R R 4 
Rhizopus spp. R R R R - 
Alternaria spp. R R R R ˃ 8 
S. brevicaulis R R R R ˃ 8 
Table 4: Radial growth inhibition of hydroalcoholic extracts (3200 µg GAE/mL) against Non-dermatophytes strains. 
 
Strains 
Growth inhibition (%)* 
B. boliviensis  B. tola  
3 days 7 days 10 days 3 days 7 days 10 days 
A. niger 26 0 0 7.3 0 0 
A. clavatus 33.3 10.6 9 24.9 10.6 9 
Penicillium spp. 28.8 33.5 39 28.8 33.5 39.1 
P.  islandicum 0 23.3 33.3 0 23.3 16.7 
A. orchidis 100 87.4 58.4 75 67.4 51.6 
Mucor spp. 84.4 77.8 20 80 75 0 
Rhizopus spp. 0 66.7 30 0 66.7 30 
Alternaria spp. 100 100 100 90 78 60 
S. brevicaulis 100 100 100 100 100 90 
*  
The percentage of radial growth inhibition was calculated as % IN= [(C – E)/ C] X100 
 
 





